Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jan 11;227(2):206-210.
doi: 10.1093/infdis/jiac334.

Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial

Sammy Huygens  1 , Quincy Hofsink  2 , Inger S Nijhof  3   4 , Abraham Goorhuis  5 , Arnon P Kater  2 , Peter A W Te Boekhorst  6 , Francis Swaneveld  7 , Věra M J Novotný  7 , Susanne Bogers  8 , Matthijs R A Welkers  9 , Grigorios Papageorgiou  10 , Bart J Rijnders  1 , Jarom Heijmans  2   11
Affiliations
Randomized Controlled Trial

Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial

Sammy Huygens et al. J Infect Dis. .

Abstract

Background: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients.

Methods: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies.

Results: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test).

Conclusions: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.

Keywords: B-cell dysfunction; COVID-19; anti-SARS-CoV-2 hyperimmune globulin; plasma-derived antibody therapy; severely immunocompromised state.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. F. S. and V. M. J. N. work at Sanquin Blood Supply Foundation. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

    1. Williamson EJ, Walker AJ, Bhaskaran K, et al. . Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584:430–6. - PMC - PubMed
    1. Vijenthira A, Gong IY, Fox TA, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 2020; 136:2881–92. - PMC - PubMed
    1. Boyarsky BJ, Werbel WA, Avery RK, et al. . Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021; 325:2204–6. - PMC - PubMed
    1. Haggenburg S, Lissenberg-Witte BI, van Binnendijk RSet al. . Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Adv 2022; 6:1537–46. - PMC - PubMed
    1. Abani O, Abbas A, Abbas F, et al. . Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021; 397:2049–59. - PMC - PubMed

Publication types

Substances